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Matrix metalloproteinases (MMPs) and adamalysin-like metalloproteinase with thrombospondin motifs
(ADAMTSs) belong to the metzincin superfamily of metalloproteinases and they play key roles in extracellular
matrix catabolism, activation and inactivation of cytokines, chemokines, growth factors, and other proteinases
at the cell surface and within the extracellular matrix. Their activities are tightly regulated in a number of ways,
such as transcriptional regulation, proteolytic activation and interaction with tissue inhibitors of metallopro-
teinases (TIMPs). Here, we highlight recent studies that have illustrated novel mechanisms regulating the
extracellular activity of these enzymes. These include allosteric activation of metalloproteinases by molecules
that bind outside the active site, modulation of location and activity by interaction with cell surface and
extracellular matrix molecules, and endocytic clearance from the extracellular milieu by low-density lipoprotein
receptor-related protein 1 (LRP1).
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Matrix metalloproteinases (MMPs) and adamalysin-
like metalloproteinases with thrombospondin motifs
(ADAMTSs) degrade extracellular matrix (ECM) mac-
romolecular components. Both MMPs and ADAMTSs
are multi-domain proteinases, with the human genome
containing 23 MMPs and 19 ADAMTSs. They are
considered to play important roles in many physiolog-
ical processes including embryonic development,
morphogenesis, tissue remodelling, cell growth, migra-
tion and apoptosis [1,2] and pathological conditions
such as inflammation, rheumatoid arthritis, osteoarthri-
tis, cardiovascular diseases, nephritis, chronicwounds,
pulmonary diseases, cancer and fibrosis [3]. The
activity of these enzymes is tightly regulated by a
number of mechanisms, and their activity is often not
readily detected in steady state tissues. Expression is
regulated transcriptionally by factors such as growth
factors, hormones, inflammatory cytokines, UV irradi-
ation, cell–cell and cell–matrix contacts, and theblished by Elsevier B.V. This is an
rg/licenses/by-nc-nd/4.0/).half-lives of their transcripts may be post-transcription-
ally regulated by microRNAs [4]. Once translated,
MMPs and ADAMTSs are produced as inactive
zymogens (pro-MMPs). Many of the MMPs and
ADAMTSs are secreted from the cell in this zymogen
form, and are then activated extracellularly by
other proteinases. The membrane-bound MMPs
(MT-MMPs) and ADAMTSs are activated intracellu-
larly by proprotein convertases such as furin. The
activity ofmaturemetalloproteinases is then regulated
by endogenous inhibitors such as α2-macroglobulin
(α2M) in blood plasma or body fluids and tissue
inhibitors of metalloproteinases (TIMPs) in the
tissue [5].
In addition to these well-recognized regulatory
mechanisms, several secreted MMPs and ADAMTSs
are known to bind to the ECM or to interact with
specific cell surface molecules or receptors. More
recently, some of the MMPs, ADAMTSs and TIMPs
have been found to be very short-lived in the
extracellular space, as they are rapidly endocytosed
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add further complexity to the regulation of metallopro-
teinase activity and ECM degradation. In this mini-
review, we focus on the effect of allosteric activators
on proMMP activation, and extracellular trafficking of
MMPs and ADAMTSs.Activation of proMMPs through
allosteric sites
ProMMPs are kept in an inactive state by
coordination of the catalytic zinc ion by the sulfhydryl
group of the Cys residue in the conserved
PRCGXPD sequence of the pro-peptide domain,
called the ‘cysteine switch’ [6]. This interaction
prevents H2O from interacting with Zn
2+ in the active
site and thus blocks catalytic activity. Disruption of
the cysteine switch Zn2+-Cys interaction can acti-
vate proMMPs, and can be triggered by (i) step-wise
cleavage of the prodomain by proteolytic enzymes
(ii) oxidation of the cysteine switch by reactive
oxidants or SH-reactive agents such as mercurial
compounds and (iii) by structural perturbation by
chaotropic agents and denaturants such as sodium
dodecyl sulfate, low pH and heat treatment [7,8].
Hypochlorous acid generated by myeloperoxidase in
macrophages and neutrophils has been shown to
oxidatively activate and subsequently inactivate
proMMP-1 and proMMP-7 [9,10]. S-nitrosylation
also activates proMMP-9 [11].
In addition, a number of reports have shown that
ECM components and cell surface molecules can
promote proMMP activation. Binding of such com-
ponents to allosteric sites on the proMMPs is thought
to induce conformational changes that disrupt the
cysteine switch. For example, insoluble elastin is
able to bind to proMMP-2 and proMMP-9, probably
through the three repeats of the fibronectin type II
(FNII) domain that are attached to the catalytic
domain. This interaction leads to auto-activation of
proMMP-2, followed by autocatalytic inactivation of
the mature enzyme [12]. However, elastin binding
does not promote proMMP-9 activation, even when
potential activator proteases are added [12].
ProMMP-9 can be allosterically activated by binding
to gelatin, without removal of the pro-domain [13]. In
both proMMP-2 and proMMP-9, the third domain of
the three FNII repeats interacts with the pro-domain
and the catalytic domain [14,15]. Gelatin, elastin and
type IV collagen bind to these FNII domains, and
may thus disturb the molecular interaction between
the pro- and catalytic domains, facilitating the
activation of proMMP-2 and proMMP-9.
ProMMP-7 can be activated on the cell surface by
interaction with the C-terminal extracellular loop of the
transmembrane tetraspanin CD151 [16] or with highly
sulfated glycosaminoglycans (GAGs) [8]. Heparin,
chondroitin-4,6-sulfate and dermatan sulfate augmentintermolecular autolytic activation of proMMP-7, while
heparan sulfate, less sulfated chondroitin sulfate and
chondroitin-2,6-sulfate are ineffective.
Activation of proMMP-2 by MT3-MMP is enhanced
by melanoma-specific chondroitin sulfate proteogly-
can, leading to an increase in cell invasion in vitro [17].
The chondroitin sulfate chain of the proteoglycan binds
to the catalytic domain of MT3-MMP and the hemo-
pexin domain of proMMP-2. Activation can also be
enhanced by the addition of isolated chondroitin-4-
sulfate, but not by chondroitin-6-sulfate, hyaluronan or
heparin. As with proMMP-7 activation, a specific
sulfation pattern has been shown to be essential for
MT3-MMP-mediated proMMP-2 activation.
A fraction of proMMP-9 secreted by the leukemic
macrophage cell-line THP-1 is covalently linked to the
core protein of a chondroitin sulfate proteoglycan.
Activation of proMMP-9 in this complex is uniquely
induced by Ca2+, but not by mercurial compounds
[18]. This involves sequential intramolecular release
of the prodomain, cleavage of the proteoglycan core
protein, truncation of a part of the hemopexin domain
and release of active MMP-9.
The hemopexin domain of proMMP-9 can also
bind to hemin and βhematin, which induces autop-
roteolytic processing of the pro-peptide and subse-
quent activation by MMP-3 [19].Regulation by location
At the cell surface
Various mechanisms focus and modulate metal-
loproteinase activity in the extracellular environment
(Fig. 1). For example, MMP-1 is considered to be a
soluble collagenase, but it binds to the I domain of α2
integrins [20]. α2β1 integrin binds native collagen I
with high affinity, clustering this integrin at contact
points in migrating keratinocytes. MMP-1 binding to
α2β1 integrin thus enables focal cleavage of
collagen; weakening adhesion to the matrix and
allowing keratinocyte migration [21]. MMP-1, colla-
gen and α2β1 integrin thus coordinate together to
drive and regulate keratinocyte migration during
re-epithelialization. Similarly, proMMP9 has been
shown to associate with α5 and β5 integrins and to
co-localise with β5 at the leading edge of invading
cells [22]. No specific effect on enzyme activity has
been demonstrated in this case, but this is clearly an
efficient localisation mechanism to focus enzyme
function where it is required.
Emmprin (CD147, basigin) is a cellmembraneMMP
regulator originally identified as an MMP-inducer. It is
a transmembrane glycoprotein with two Ig-like do-
mains that interacts with a number of othermembrane
proteins, including caveolin, cyclophilin 60 and mono-
carboxylate transporters, as well as proMMP-1 and
Fig. 1. Extracellular regulation of metalloproteinases: Metalloproteinases (shown in green) are regulated in the extracellular
environment by a number of mechanisms, including binding to the ECM, proteolytic and allosteric activation, interaction with
endogenous inhibitors (shown in red), interaction with a variety of cell surface molecules, and endocytic trafficking.
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emmprin-bound MMP-1 has not been examined, this
may be another way to specifically regulate pericel-
lular collagenolytic activity.
MMP-7 binds to cell surface cholesterol sulfate and
induces adhesion of colon cancer cells by cleavage of
cell surface proteins [25]. This lipid interaction
promotes the proteolytic activity of MMP-7 toward
particular substrates such as fibronectin and lami-
nin-332 in the pericellular ECM [26]. The cholesterol
sulfate-binding site is located on the opposite side of
MMP-7 to that bearing the catalytic cleft [27], which is
thought to position the enzyme in a manner that
enables it to cleave protein substrates both on the cell
surface and in the pericellular ECM.
MT1-MMP colocalizes with β1 integrin in some cell
types and this appears to regulate its function. Plating
of endothelial cells on β1 integrin-interacting matrices
such as collagen I, fibronectin and fibrinogen leads to
the upregulation of MT1-MMP and co-localisation of
the enzyme with β1 integrin at cell–cell junctions [28].
Upregulation of MT1-MMP was shown to be due to a
reduction in its endocytic uptake by the cells. Similarly,
clustering of α3β1 integrin promotes trafficking of
MT1-MMP to aggregated integrin complexes in
ovarian cancer cells, leading to increased proMMP-2
activation [29]. MT1-MMP associates with αvβ3
integrin in motility-associated structures on migrating
endothelial cells [28]. Interaction of MT1-MMP with
αvβ8 activates latent transforming growth factor β1
(TGFβ1), where αvβ8 integrin forms a complex with
the TGFβ1 latency associated peptide (LAP) and
MT1-MMP [30].Tetraspanins may also regulate MT1-MMP func-
tion on the cell surface. MT1-MMP colocalizes with
the tetraspanin CD151 and its associated partner
α3β1 integrin at lateral cell junctions in endothelial
cells [31]. Another tetraspanin, CD63, a component
of late endosomal and lysosomal membranes,
interacts with the hemopexin domain of MT1-MMP
which enhances internalization and lysosomal deg-
radation of MT1-MMP [32], whereas several tetra-
spanins are thought to chaperone newly synthesised
MT1-MMP to the cell surface, preventing its lyso-
somal degradation and supporting its function at the
cell surface [33].
Collagen internalization also regulates MT1-MMP
activity [34]. The endocytic mannose receptor C type
2, Endo180, internalizes collagen and its depletion in
HT1080 cells by siRNA results in the accumulation
of collagen in the medium and an increase of
MT1-MMP activity on the cell surface. This suggests
that there is an intricate coordination of collagen
clearance in the pericellular environment mediated
by both collagen internalization and regulated
MT1-MMP activity.
Binding to the ECM
Some metalloproteinases have their localization,
activity and substrate specificity modulated by
interaction with components of the ECM, such as
sulfated GAGs. Heparin solubilizes MMP-2, MMP-7,
MMP-9 and MMP-13 from tissues [35], and MMP-1,
MMP-3 [36], MMP-2 [37], MMP-9 [38] and MMP-13
[39] bind to heparin in vitro, suggesting that these
258 Regulation of MPs in the extracellular environmentmetalloproteinases may bind to sulfated GAGs in the
ECM. MMP-1, MMP-2 and MMP-9 are known to bind
to heparin via their hemopexin domains [40,41],
while ADAMTS-1 [42], ADAMTS-4 [43] and
ADAMTS-5 [44] bind to the ECM via their ancillary
domains. Other ADAMTSs with homologous C-ter-
minal domains are also likely to bind to the ECM.
ECM binding can regulate metalloproteinase activ-
ity by dictating or limiting access to substrates or by
directly modulating activity. For example, heparin
inhibits ADAMTS-4 hydrolysis of aggrecan, and has
a greater effect on hydrolysis of the interglobular
domain than of the chondroitin sulfate attachment
region [45]. This suggests that ECM binding may alter
the substrate preference of ADAMTSs. Additionally,
ECM binding can affect the interaction of metallopro-
teinases with TIMP-3, the only TIMP that binds to the
ECM. GAGs increase TIMP-3 affinity for MMP-2, −7
[46], ADAMTS-2 [47], ADAMTS-4 and ADAMTS-5
[48], and this is likely to be the case for other sulfated
GAG-binding metalloproteinases. Notably, the ability
of sulfated GAGs to increase the affinity between
TIMP-3 and ADAMTS-4 and ADAMTS-5 is highly
dependent on the sulfation pattern of the GAG [49].Endocytosis
Regulation of metalloproteinases and TIMPs
by LRP1
Low-density lipoprotein (LDL) receptor-related pro-
tein 1 (LRP1, or CD91) is a member of a family of
scavenger receptors related to the LDL receptor [50].
It is a type I transmembrane protein consisting of a
515-kDa α-chain containing the extracellular ligand-
binding domains and a non-covalently associated
85-kDa β-chain containing a transmembrane domain
and a short cytoplasmic tail. The α- and β-chains are
derived from a single polypeptide chain that is cleaved
by furin during maturation. LRP1 was first character-
ized as a receptor for apolipoprotein E-containing
lipoprotein particles [51] and for α2M-proteinase
complexes [52]. The α2M-proteinase complexes
were shown to be endocytosed within 1 h by a
clathrin-dependent pathway [53]. This endocytic
process is a general mechanism to eliminate excess
active proteinases from tissues and body fluids, since
most extracellular endopeptidases with different
catalytic mechanisms can react with and be
entrapped by α2M [54]. It is now known that a number
of proteases (both active and precursor forms), their
endogenous inhibitors and protease-inhibitor com-
plexes can bind to and be internalized by LRP1. More
than 40 ligands have been identified to date, including
lipoproteins, thrombospondins, fibronectin, amyloid β,
peptide, lactoferrin, rhinovirus, and growth factors
such as connective tissue growth factor, TGFβ,midkine and platelet-derived growth factor [55,56],
and the list is still growing. The importance of LRP1 in
biological processes is demonstrated by the lethality
of LRP1 gene deletion at an early stage of murine
embryonic development [57]. This indicates that
endocytic scavenging of bioactive molecules is
essential to maintain tissue homeostasis and that
disruption of this process may result in pathological
conditions.
LRP1-mediated endocytosis of MMPs was discov-
ered much later than that of other proteases. The
Partridge group [58] first reported that rat MMP-13
disappeared from the culture medium of a rat
osteoblast cell line and demonstrated that this
occurred through a receptor-mediated process. Sub-
sequently, the disappearance was shown to be due to
endocytosis of MMP-13 by LRP1 with the assistance
of a 170 kDa MMP-13-specific receptor [59]. Other
metalloproteinases currently known to be endocy-
tosed by LRP1 are MMP-9 [60], MMP-9-TIMP-1
complexes [61], MMP-2-thrombospondin 2 com-
plexes [62], proMMP-2-TIMP-2 complexes [63],
ADAMTS-4 [64] and ADAMTS-5 [65]. In addition,
TIMP-1 [66], TIMP-2 [67] and TIMP-3 [68] can be
endocytosed by LRP1. The rate of their endocytosis
varies depending on their affinities for LRP1 [64].
Ectodomain shedding of LRP1
ADAMTS-4 and ADAMTS-5 are two major aggre-
can-degrading proteinases (‘aggrecanases’) in carti-
lage and they are considered to play a key role in the
development of osteoarthritis (OA). However, mRNA
levels for ADAMTS-5 are not significantly elevated in
OA compared to normal cartilage (see [69,70] for
review) and how ADAMTS-5 activity is regulated has
not been clear. Studies by Yamamoto et al. [65] shed
new insight into the regulation of ADAMTS-5 in OA,
showing that endocytic clearance of ADAMTS-5 by
LRP1 is impaired in OA chondrocytes due to a
reduction in LRP1 protein levels. No reduction in
LRP1 mRNA levels was observed. A reduction in
MMP-13 endocytosis in OA chondrocytes was also
reported [71]. Reduction in cell surface levels of LRP1
may be due to increased shedding of the receptor
ectodomain. Quinn et al. [72] first demonstrated that
LRP1 can be shed through the action of a metallopro-
teinase that cleaves the receptor at the membrane
proximal region of the β-chain in human BeWo
trophoblast cells. LRP1 shedding is increased in
malignant cells [73,74] and under inflammatory condi-
tions such as in rheumatoid arthritis and systemic lupus
erythematosus [75]. Proteinases reported to shed
LRP1 include β-amyloid precursor protein-cleaving
enzyme (BACE) [76], MT1-MMP [74], ADAM10 [77],
ADAM12 [74] and ADAM17 [77]. Shed LRP1 retains
ligand-bindingcapacity andcanact asadecoy receptor
[78]. Recently, Scilabra et al. [68] reported that shed
LRP1 competes with cell surface LRP1 for binding to
259Regulation of MPs in the extracellular environmentTIMP-3, and that extracellular LRP1-TIMP-3 com-
plexes retain their ability to inhibit target metallopro-
teinases. Shed LRP1 also binds to ADAMTS-4,
ADAMTS-5 and MMP-13 and prevents them being
endocytosed (K. Yamamoto, unpublished result). We
thus speculate that an increase in LRP1 shedding
alters the trafficking of key ECM-degrading enzymes
and their inhibitor TIMP-3 (Fig. 2). In articular cartilage,
such changes appear to shift the homeostatic balance
of ECM turnover toward catabolism. In fact, the
addition of the LRP1-ligand binding antagonist to
normal cartilage in culture increases aggrecan deg-
radation [65].
Many LRP1 ligands bind to heparin, and heparin
competes with LRP1 for binding to ligands. Sulfated
glycans may thus shift the extracellular trafficking of
LRP1 ligands (Fig. 2). In this regard, Troeberg et al.
[49] reported that endocytic removal of TIMP-3 was
inhibited by heparin, heparan sulfate proteoglycans
and chondroitin sulfate E, making TIMP-3 available
for metalloproteinase inhibition. In addition, the
sulfated GAG-TIMP-3 complex has higher affinity
for ADAMTS-4 and ADAMTS-5 than TIMP-3 alone,
but the sulfation pattern of the GAG is crucial for this
activity.Fig. 2. Trafficking of metalloproteinases and TIMPs
metalloproteinases (including MMP-13, ADAMTS-4 and AD
TIMP-2, TIMP-3, shown in red) can either bind to the ECM or b
trafficking equilibrium determines net ECM turnover, and can
shedding of LRP1.Endocytic regulation of MT-MMPs
Endocytosed MT-MMPs can either be trafficked to
lysosomes for degradation or recycled back to the cell
surface [79,80]. MT1-MMP can be internalized by two
distinct (clathrin- and caveolae-dependent) endocytic
pathways. Clathrin-dependent endocytosis is initiated
by interaction of the μ2 subunit of adaptor protein 2
with the LLY sequence in the MT1-MMP cytoplasmic
tail [81]. Caveolae-dependent endocytosis of
MT1-MMP plays an important role in endothelial cell
migration on a collagen substratum [82]. The definitive
role of these independent pathways is unclear, but it
has been hypothesized that they may be responsible
for internalizing different subpopulations of MT1-MMP
at the cell surface, as they differ in speed and
localization of internalization. A recent study revealed
that α2M induces cellular migration of Muller glial
cells by endocytic recycling and intracellular distribu-
tion of MT1-MMP toward cellular protrusions [83].
AlthoughMT1-MMPdoes not bind to LRP1 directly, its
activity is regulated by LRP1-mediated endocytosis
via α2M. As discussed above, CD63 tetraspanin
promotes MT1-MMP internalization and lysosomal
degradation [32].between LRP1 endocytic receptor and ECM. Some
AMTS-5, shown in green) as well as TIMPs (TIMP-1,
e endocytosed by the LRP1 receptor. The balance of this
be modulated by the pattern of sulfation on HSPGs or by
260 Regulation of MPs in the extracellular environmentConclusions and future directions
A number of studies, including those highlighted in
this review, have demonstrated that metalloprotein-
ases interact with a far wider range of molecules on
the cell surface and in the extracellular environment
than was previously appreciated. In most cases, the
functional consequences of such binding on enzyme
activity, stability, substrate specificity and affinity for
endogenous inhibitors are not known. Such interac-
tions may greatly increase the complexity of metal-
loproteinase regulation in both health and disease,
and warrant further investigation. Most importantly,
research is needed to relate the current in vitro
observations to the situation in vivo. Such under-
standing may be of help in designing strategies to
inhibit metalloproteinase activity in a targeted man-
ner in pathological conditions.
Similarly, our understanding of allosteric activation
of metalloproteinases by their substrates or other
binding partners is limited. The demonstration that
binding of elastin to an allosteric site on proMMP-2
promotes activation of the enzyme raises the
possibility that other matrix molecules or substrates
may similarly activate extracellular zymogens. This
interplay between metalloproteinases and their
substrates is also likely to be amenable to targeted
pharmacological intervention.
We are coming to appreciate that endocytic process-
es, including LRP1-mediated endocytosis, represent
importantmechanisms for regulatingmetalloproteinase
activity, modulating extracellular levels of the enzymes
and their endogenous inhibitors. In addition to endocy-
tic scavenger functions, LRP1 can act as a signalling
receptor via interaction of its cytoplasmic domain with
various scaffolding and signalling proteins. A recent
study by the Gonias group indicates that LRP1 can
initiate different signalling pathways in response to
binding of particular ligands to its extracellular domain
[84]. This raises the possibility that LRP1-mediated
uptake of metalloproteinases and their inhibitors is not
merely a mechanism for clearing them from the
extracellular environment, but that it also serves to
deliver information to cells about turnover of their
surrounding environment.
Several of the metalloproteinases and their inhib-
itors studied to date are able to bind to both LRP1
and to sulfated GAGs in the ECM, with their
extracellular availability determined by their relative
affinity for each. Affinity of proteins for GAGs is
dependent on the specific sulfation pattern of the
GAG, and factors affecting this sulfation pattern
(such as expression of sulfatases and GAG biosyn-
thesis enzymes) thus modulate extracellular traffick-
ing of such metalloproteinases and their inhibitors.
Since LRP1 has many potential ligands, the role of
competition between ligands for binding and endo-
cytosis could also regulate metalloproteinase and
TIMP removal from the extracellular space.Determining how metalloproteinase activity is reg-
ulated in the complex pericellular environment is likely
to be technically challenging, but such information will
greatly increase our understanding of the physiolog-
ical interactions of the enzymes, and how their activity
becomes disrupted in disease.Acknowledgements
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